Showing 1981-1990 of 3189 results for "".
Harnessing Mobile Technology in Concert with EHRs
https://practicaldermatology.com/topics/practice-management/harnessing-mobile-technology-in-concert-with-ehrs/21637/Significant developments are on the way, but already EHRs offer unique abilities via mobile and tablet technologies.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21961/Dermatology Q&A: First Head-to-Head Data Highlight Safety and Efficacy of Biologics
https://practicaldermatology.com/topics/psoriasis/first-head-to-head-data-highlight-safety-and-efficacy-of-biologics/22032/A lead investigator on the first head-to-head trial of biologics shares insights on the future of biologic research and therapy.Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
https://practicaldermatology.com/programs/cme/data-driving-recent-guideline-updates-in-neoadjuvant-therapy-for-resectable-melanoma/36322/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
https://practicaldermatology.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-braf-mutant-stage-iv-melanoma/36328/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
https://practicaldermatology.com/programs/cme/emerging-and-practice-changing-data-in-immunotherapy-strategies-for-melanoma/36330/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
https://practicaldermatology.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
https://practicaldermatology.com/programs/cme/clinical-implications-of-neoadjuvant-therapy-guideline-updates-in-resectable-melanoma/36323/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.